Triptorelin is a synthetic peptide analog of gonadotropin-releasing hormone (GnRH) that is used in the treatment of hormone-related disorders such as prostate cancer, breast cancer, and endometriosis. The market for triptorelin is expected to grow significantly due to the rising prevalence of hormone-related disorders.
Prostate Cancer: Prostate cancer is the second most common cancer in men and is expected to affect approximately 1 in 8 men in their lifetime. Androgen deprivation therapy (ADT) is a standard treatment for advanced prostate cancer, which involves the use of drugs such as triptorelin to suppress the production of testosterone. According to a report by the American Cancer Society, there were an estimated 248,530 new cases of prostate cancer in the United States in 2021.
Breast Cancer: Breast cancer is the most common cancer in women and is the second leading cause of cancer-related deaths among women. Hormone receptor-positive (HR+) breast cancer accounts for approximately 75% of all breast cancers. ADT is also used in the treatment of HR+ breast cancer, which involves the use of drugs such as triptorelin to suppress the production of estrogen. According to a report by the American Cancer Society, there were an estimated 281,550 new cases of invasive breast cancer in the United States in 2021.
Endometriosis: Endometriosis is a condition where the tissue that lines the uterus grows outside of the uterus, causing pain and infertility. Hormonal therapies such as triptorelin are used in the treatment of endometriosis to suppress the production of estrogen and reduce the growth of endometrial tissue. According to a report by the World Endometriosis Society, approximately 10% of women of reproductive age are affected by endometriosis.
The rising prevalence of hormone-related disorders is expected to drive the demand for triptorelin in the coming years. According to a report by Grand View Research, the global triptorelin market size was valued at USD 347.2 million in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 4.4% from 2021 to 2028.
In addition, increasing healthcare expenditure, the growing geriatric population, and advancements in drug delivery technologies are expected to further fuel the growth of the triptorelin market.
In conclusion, the rising prevalence of hormone-related disorders such as prostate cancer, breast cancer, and endometriosis is expected to drive the demand for triptorelin in the coming years. As a result, the market for triptorelin is expected to grow significantly.
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Everest Market Insights journalist was involved in the writing and production of this article.